Provided by Tiger Fintech (Singapore) Pte. Ltd.

PTC Therapeutics

49.95
+0.43000.87%
Post-market: 49.950.00000.00%17:34 EDT
Volume:984.81K
Turnover:49.21M
Market Cap:3.94B
PE:-10.57
High:50.43
Open:49.88
Low:49.03
Close:49.52
Loading ...

PTC Therapeutics Inc: Anticipates Total Revenues for Full-Year 2025 to Be Between $600 Mln and $800 Mln

THOMSON REUTERS
·
13 Jan

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43Rd Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
13 Jan

RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating

MT Newswires Live
·
07 Jan

Novartis' Gene Therapy Meets Primary Endpoint in SMA Study

Zacks
·
01 Jan

Novartis gene therapy helps children with rare muscle disorder in study

Reuters
·
30 Dec 2024

PTC Therapeutics Files NDA With US FDA for Vatiquinone to Treat Friedreich's Ataxia

MT Newswires Live
·
19 Dec 2024

BRIEF-Ptc Therapeutics Announces Vatiquinone NDA Submission To FDA For The Treatment Of Children And Adults Living With Friedreich Ataxia

Reuters
·
19 Dec 2024

PTC Therapeutics submits NDA for vatiquinone in Friedreich ataxia

TIPRANKS
·
19 Dec 2024

PTC Therapeutics Inc: PTC's Fourth Approval Application Submitted to FDA in 2024

THOMSON REUTERS
·
19 Dec 2024

PTC Therapeutics Announces Vatiquinone Nda Submission to FDA for the Treatment of Children and Adults Living With Friedreich Ataxia

THOMSON REUTERS
·
19 Dec 2024

BRIEF-Ptc Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
18 Dec 2024

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
18 Dec 2024

Morgan Stanley Upgrades PTC Therapeutics to Overweight From Equalweight, Raises Price Target to $67 From $45

MT Newswires Live
·
13 Dec 2024

PTC Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley

TIPRANKS
·
13 Dec 2024

Cantor Fitzgerald says ‘aggressively’ buy uniQure, PTC Therapeutics

TIPRANKS
·
10 Dec 2024

Novartis Announces Positive Results From Late-Stage Study on Fabhalta

Zacks
·
10 Dec 2024

PTC Therapeutics: Hold Rating Amid Strategic Collaboration with Novartis and Clinical Uncertainties

TIPRANKS
·
06 Dec 2024

PTC Therapeutics (PTCT) Receives a Hold from Barclays

TIPRANKS
·
05 Dec 2024

PTC Therapeutics Is Maintained at Sell by Goldman Sachs

Dow Jones
·
04 Dec 2024

PTC Therapeutics price target raised to $32 from $26 at Citi

TIPRANKS
·
04 Dec 2024